文献速递乳腺技术与安全US

COVID-19疫苗加强针后腋窝淋巴结病的超声随访消退时间及相关因素

Axillary Lymphadenopathy After a COVID-19 Vaccine Booster Dose: Time to Resolution on Ultrasound Follow-Up and Associated Factors.
PubMed 文献 · AJR Am J Roentgenol · 2023-03-08

本研究回顾性纳入54例接种mRNA COVID-19疫苗加强针后超声发现同侧腋窝淋巴结病的患者,随访至淋巴结消退。淋巴结病平均消退时间为接种后102天,且显著短于初次系列接种后的129天。年龄、疫苗类型和乳腺癌史与消退时间无关。

要点

  • 加强针后腋窝淋巴结病平均102天消退,短于初次接种的129天。
  • 疑似疫苗相关淋巴结病建议随访间隔至少12周。
  • 年龄、疫苗种类和乳腺癌史不影响消退时间。

核心结论

  • COVID-19疫苗加强针后腋窝淋巴结病平均消退时间为102天,短于初次系列接种后的129天。

研究设计与样本

  • 回顾性单中心研究,纳入54例(平均年龄57岁)接种mRNA COVID-19疫苗加强针后超声发现同侧腋窝淋巴结病的患者,随访至淋巴结消退,并与既往64例初次系列接种患者比较。

关键影像表现/征象

  • 超声显示注射同侧腋窝淋巴结病,多数为筛查检查(33例)或诊断检查(21例)发现,仅2例有腋窝疼痛症状。

诊断标准与关键数值

  • 加强针后淋巴结病平均消退时间102±56天(接种后)和84±49天(首次超声发现后);初次系列接种后平均129±37天,差异有统计学意义(p=.01)。

临床应用与阅片要点

  • 对于COVID-19疫苗加强针后疑似疫苗相关腋窝淋巴结病,建议随访间隔至少12周,以避免不必要的活检。

局限性

  • 回顾性单中心设计,样本量有限,仅纳入随访至淋巴结消退的患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Because administration of booster doses of COVID-19 vaccines is ongoing, radiologists are continuing to encounter COVID-19 vaccine-related axillary lymphadenopathy on imaging. OBJECTIVE. The purposes of this study were to assess time to resolution of COVID-19 vaccine-related axillary lymphadenopathy identified on breast ultrasound after administration of a booster dose and to assess factors potentially associated with time to resolution. METHODS. This retrospective single-institution study included 54 patients (mean age, 57 years) with unilateral axillary lymphadenopathy ipsilateral to the site of injection of a booster dose of messenger RNA COVID-19 vaccine visualized on ultrasound (whether an initial breast imaging examination or follow-up to prior screening or diagnostic breast imaging) performed between September 1, 2021, and December 31, 2022, and who underwent follow-up ultrasound examinations until resolution of lymphadenopathy. Patient information was extracted from the EMR. Univariable and multivariable linear regression analyses were used to identify predictors of time to resolution. Time to resolution was compared with that in a previously described sample of 64 patients from the study institution that was used to evaluate time to resolution of axillary lymphadenopathy after the initial vaccination series. RESULTS. Six of the 54 patients had a history of breast cancer, and two had symptoms related to axillary lymphadenopathy (axillary pain in both patients). Among the 54 initial ultrasound examinations showing lymphadenopathy, 33 were screening examinations and 21 were diagnostic examinations. Lymphadenopathy had resolved a mean of 102 ± 56 (SD) days after administration of the booster dose and 84 ± 49 days after the initial ultrasound showing lymphadenopathy. Age, vaccine booster type (Moderna vs Pfizer-BioNTech), and history of breast cancer were not significantly associated with time to resolution in univariable or multivariable analyses (all p > .05). Time to resolution after administration of a booster dose was significantly shorter than time to resolution after administration of the first dose in the initial series (mean, 129 ± 37 days) (p = .01). CONCLUSION. Axillary lymphadenopathy after administration of a COVID-19 vaccine booster dose has a mean time to resolution of 102 days, shorter than the time to resolution after the initial vaccination series. CLINICAL IMPACT. The time to resolution after administration of a booster dose supports the current recommendation for a follow-up interval of at least 12 weeks when vaccine-related lymphadenopathy is suspected.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Mema, Lane, Drotman, et al. Axillary Lymphadenopathy After a COVID-19 Vaccine Booster Dose: Time to Resolution on Ultrasound Follow-Up and Associated Factors. AJR Am J Roentgenol. 2023. PMID: 36883774. doi:10.2214/AJR.22.28970

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。